TARA PROTARA THERAPEUTICS INC
Permanent stock page ↗Health Care · Russell 2000
Next earnings: Tue 10 Nov 2026 · estimated
What 11 analyst firms say about PROTARA THERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 11 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 3 reports on TARA from 3 analyst firms in the last 90 days (11 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Li Watsek | Buy | 15 Oct 2026 | — |
| H.C. Wainwright | Andres Y Maldonado | Buy | 12 Aug 2026 | 27.00 USD |
| H.C. Wainwright | Andrew S. Fein | Buy | 20 May 2026 | — |
| Jonestrading | Boris Peaker | Buy | 6 Apr 2026 | 25.00 USD |
| JPMorgan | Brian Cheng | Buy | 14 May 2026 | 26.00 USD |
| Lifesci Capital | Charles Zhu | Buy | 23 Feb 2026 | 26.00 USD |
| Oppenheimer | Leland Gershell | Buy | 20 May 2026 | 28.00 USD |
| Piper Sandler | Kelsey Goodwin | Buy | 13 May 2026 | 24.00 USD |
| TD Cowen | Stacy Ku | Buy | 21 May 2026 | 30.00 USD |
| UBS | Unnamed analyst | Buy | 20 May 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:25 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.